Yun Zhong
Stock Analyst at Wedbush
(0.58)
# 3,860
Out of 4,761 analysts
26
Total ratings
30.43%
Success rate
-16.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PASG Passage Bio | Assumes: Outperform | $4 | $0.52 | +662.20% | 2 | Nov 29, 2024 | |
| MLTX MoonLake Immunotherapeutics | Assumes: Outperform | $92 → $73 | $42.33 | +72.45% | 1 | Nov 5, 2024 | |
| RZLT Rezolute | Initiates: Outperform | $12 | $4.53 | +164.90% | 1 | Nov 5, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Outperform | $58 | $38.75 | +49.68% | 1 | Nov 5, 2024 | |
| AVXL Anavex Life Sciences | Maintains: Buy | $35 → $28 | $8.35 | +235.33% | 2 | Feb 9, 2023 | |
| TSHA Taysha Gene Therapies | Downgrades: Neutral | n/a | $1.61 | - | 2 | Feb 2, 2023 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $14 → $16 | $9.19 | +74.10% | 1 | Jan 18, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $125 → $160 | $106.28 | +50.55% | 11 | Dec 22, 2022 | |
| RCKT Rocket Pharmaceuticals | Initiates: Buy | $35 | $10.47 | +234.29% | 1 | Nov 1, 2022 | |
| BLUE bluebird bio | Downgrades: Hold | $700 | $4.08 | +17,056.86% | 2 | Jul 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $12.84 | +258.26% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.85 | +250.88% | 1 | May 5, 2021 |
Passage Bio
Nov 29, 2024
Assumes: Outperform
Price Target: $4
Current: $0.52
Upside: +662.20%
MoonLake Immunotherapeutics
Nov 5, 2024
Assumes: Outperform
Price Target: $92 → $73
Current: $42.33
Upside: +72.45%
Rezolute
Nov 5, 2024
Initiates: Outperform
Price Target: $12
Current: $4.53
Upside: +164.90%
Protagonist Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $58
Current: $38.75
Upside: +49.68%
Anavex Life Sciences
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $8.35
Upside: +235.33%
Taysha Gene Therapies
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.61
Upside: -
Amicus Therapeutics
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $9.19
Upside: +74.10%
Sarepta Therapeutics
Dec 22, 2022
Maintains: Buy
Price Target: $125 → $160
Current: $106.28
Upside: +50.55%
Rocket Pharmaceuticals
Nov 1, 2022
Initiates: Buy
Price Target: $35
Current: $10.47
Upside: +234.29%
bluebird bio
Jul 1, 2021
Downgrades: Hold
Price Target: $700
Current: $4.08
Upside: +17,056.86%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $12.84
Upside: +258.26%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $2.85
Upside: +250.88%